Comparison of Superb Microvascular Imaging(SMI) and Contrast SMI for detection of angiogenesis in Thyroid tumor

Comparison of Superb Microvascular Imaging(SMI) and Contrast SMI for detection of angiogenesis in Thyroid tumor - Comparison of Superb Microvascular Imaging(SMI) and Contrast SMI for detection of angiogenesis in Thyroid tumor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024761

Enrollment

100

Registered

2016-12-01

Start date

2017-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid tumor

Interventions

Thyroid tumor group US examinations were performed with a diagnostic ultrasound system (Aplio-500

Toshiba, Tokyo, Japan) Sonazoid was injected intravenously (bolus, 0.015 mL/kg).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients planned examination of ultrasound for diagnosis of Thyroid tumor 2) patients who consented to participate in this study

Exclusion criteria

Exclusion criteria: 1) history of allergy to Sonazoid 2) history of allergy to eggs or egg products 3)Right to left shunts in heart or lung 4)Severe heart diseases 5)Severe lung diseases 6)Patients who plan to undergo digestive tract examination on the same day of contrast-enhanced ultrasonography 7)Pregnancy and possibility of the pregnancy or patients under the nursing 8)Not eligible for this study judged by doctors

Design outcomes

Primary

Measure	Time frame
Sensitibity, Specificity	—

Countries

Japan

Contacts

Public ContactKazutaka Nakashima

Kawasaki Medical School Depertment of General Surgery

urbandoc@med.kawasaki-m.ac.jp086-225-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026